SAVING’ jab for severe asthma that could prevent deadly attacks with just two doses a year could be available to patients in ...

The FDA approved depemokimab as an add-on maintenance treatment in patients aged at least 12 years with severe asthma and an eosinophilic phenotype, according to a press release from GSK.Depemokimab ...

Two replicate phase 3 trials of GB-0895, an anti-thymic stromal lymphopoietin antibody, are enrolling adults and adolescents ...

The FDA approved depemokimab (Exdensur) as the first ultra-long-acting biologic with twice-yearly dosing approved for patients with severe asthma with an eosinophilic phenotype, GSK announced.

WASHINGTON - The Food and Drug Administration has approved Exdensur as an add-on maintenance treatment for patients aged 12 and older with severe eosinophilic asthma, making it the first biologic ...

The U.S. Food and Drug Administration has approved Exdensur (depemokimab-ulaa) as an add-on maintenance treatment for severe ...

More must be done to ensure that asthma patients get access to cutting-edge treatments, experts have said, after research ...

Marketed as Exdensur, the ultra-long-acting biologic is the first of its kind, requiring only two injections per year to ...

The Food and Drug Administration (FDA) has approved Exdensur (depemokimab-ulaa), an interleukin-5 antagonist, for add-on maintenance treatment of severe asthma characterized by an eosinophilic ...

What starts as breathlessness can turn fatal within minutes, doctors warn that quick action, correct inhaler use and timely ...

Patients with severe asthma continue to have residual disease despite initiating treatment with biologics, and severe uncontrolled asthma is associated with higher economic burden compared with ...

This transcript has been edited for clarity. Michael Wechsler, MD: Hello. I'm Dr Mike Wechsler and welcome to Medscape's InDiscussion series on moderate to severe asthma. This is episode three of the ...